Experts explore innovative bridging therapies for multiple myeloma, enhancing patient outcomes before CAR T-cell treatment while addressing significant challenges.
Dr Dhakal on Sequential Targeting in Myeloma
Researchers explore talquetamab as a bridge therapy for multiple myeloma patients before CAR T-cell treatment, assessing safety and efficacy outcomes.
A clinical study reveals talquetamab's effectiveness as a bridging therapy before CAR T-cell treatment for multiple myeloma, enhancing patient outcomes.
A study shows talquetamab is a safe, effective bridge for high-risk patients, potentially improving outcomes and mitigating CAR T toxicities.